ACMG 2025 | March 18-22, 2025 | Los Angeles, California | Booth #610
Visit Asuragen, a Bio-Techne brand at Booth #610, and join us at these sessions to learn how our products & services can empower you to provide better answers.
Exhibit Theater
Revolutionizing Complex Variant Characterization:
A Nanopore Sequencing Based Single Workflow Kit For 11 Hard to Decipher Carrier Screening Associated Genes
Speaker: Ninad Pendse,
Senior Product Manager
Asuragen, a Bio-Techne brand
Thursday, March 20th
11:20 AM - 11:50 AM PST
Exhibit Theater One

Visit Our Poster – A 2025 Top Rated Abstract!
View new data reinforcing our commitment to comprehensive genetic coverage:
Verification of a Software and Amplification-Based Nanopore Sequencing Solution to Characterize Complex Variants in 11 Challenging, High-Frequency Carrier Genes
Presenting Author: Juliette Baker,
Advanced Research Associate,
Asuragen, a Bio-Techne brand
Friday, March 21st
10:30 AM - 11:30 AM PST
P804

New Product Spotlight
AmplideX® Nanopore Carrier Plus Kit*†
AmplideX® Nanopore Carrier Plus Kit*†
Streamlining Carrier Screening Insights, Even for the Most Challenging Genes
Asuragen is leveraging its gold-standard PCR chemistry with Oxford Nanopore’s long-read DNA sequencing capabilities to develop the first sequencing system to resolve the most challenging, high-prevalence carrier genes in a single, unified workstream that today requires multiple other methods.

Kitted Assays for Inherited Genetic Disorders
Kitted Assays for Inherited Genetic Disorders
The AmplideX® suite of products helps solve unmet testing needs in inherited genetic disorders by leveraging expertise in reliable amplification of GC-rich and high homology target sequences like FMR1. Asuragen’s AmplideX technology lends accuracy, sensitivity, and specificity to analysis of other hard-to-amplify genetic targets and is designed for seamless integration with established laboratory equipment, ensuring accessibility and ease of adoption.
Assays and included data reporting solutions are designed with labs in mind to optimize efficiency, reduce hands-on time, and minimize costs. Driven by the pursuit of unraveling the complexities of inherited genetic disorders, Asuragen’s AmplideX technology empowers you to provide better answers.
*For Research Use Only. Not for use in diagnostic procedures.
†This product is under development; performance characteristics and final product features to be determined.